Nektar Therapeutics (NKTR)
(Delayed Data from NSDQ)
$1.36 USD
+0.07 (5.43%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $1.35 -0.01 (-0.74%) 7:58 PM ET
2-Buy of 5 2
C Value D Growth D Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$1.36 USD
+0.07 (5.43%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $1.35 -0.01 (-0.74%) 7:58 PM ET
2-Buy of 5 2
C Value D Growth D Momentum D VGM
Zacks News
Why Is Esperion Therapeutics (ESPR) Down 3.9% Since Last Earnings Report?
by Zacks Equity Research
Esperion Therapeutics (ESPR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
What Makes Nektar (NKTR) a New Buy Stock
by Zacks Equity Research
Nektar (NKTR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Nektar's (NKTR) Q2 Earnings Lag Estimates, Revenues Top
by Zacks Equity Research
Nektar (NKTR) reports a wider-than-expected loss in the second quarter of 2024 while revenues beat estimates. Stock falls in after-hours trading.
Nektar Therapeutics (NKTR) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Nektar (NKTR) delivered earnings and revenue surprises of -19.05% and 36.26%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Jazz Pharmaceuticals (JAZZ) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Jazz (JAZZ) delivered earnings and revenue surprises of 13.25% and 2.04%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Nektar's (NKTR) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Nektar (NKTR) reports a narrower-than-expected loss in the first quarter of 2024 and tops revenue estimates.
Nektar (NKTR) Up 7.5% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Nektar (NKTR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Nektar (NKTR) Begins Phase IIb Study Rezpeg in Alopecia Areata
by Zacks Equity Research
The placebo-controlled, phase IIb study will investigate the efficacy and safety of Nektar's (NKTR) rezpeg in patients with severe to very severe alopecia areata.
Nektar (NKTR) Q4 Loss Wider Than Expected, Revenue Beat
by Zacks Equity Research
Nektar (NKTR) reports a wider-than-expected loss in the fourth quarter of 2023 while revenue beat estimates.
Nektar Therapeutics (NKTR) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Nektar (NKTR) delivered earnings and revenue surprises of -10% and 39.75%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Will Nektar Therapeutics (NKTR) Report Negative Q4 Earnings? What You Should Know
by Zacks Equity Research
Nektar (NKTR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BioCryst (BCRX) Moves 25.6% Higher: Will This Strength Last?
by Zacks Equity Research
BioCryst (BCRX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Why Is Jazz (JAZZ) Up 2.6% Since Last Earnings Report?
by Zacks Equity Research
Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Nektar (NKTR) Up 4% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Nektar (NKTR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Nektar Therapeutics (NKTR) Incurs Wider-Than-Expected Q3 Loss
by Zacks Equity Research
Nektar (NKTR) misses third-quarter estimates for the bottom line but beats the same for the top line.
Nektar Therapeutics (NKTR) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Nektar (NKTR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Nektar (NKTR), Cellular Biomedicine Join for Lung Cancer Studies
by Zacks Equity Research
Nektar (NKTR) enters into a deal with Cellular Biomedicine Group to develop NKTR-255 in combination with C-TIL05 to treat advanced NSCLC.
Nektar (NKTR) Up on Positive New Data From Eczema Study
by Zacks Equity Research
Nektar (NKTR) gains on positive new data for its pipeline candidate, rezpegaldesleukin, evaluated from an early-stage study for treating atopic dermatitis.
Why Is Nektar (NKTR) Down 37.1% Since Last Earnings Report?
by Zacks Equity Research
Nektar (NKTR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
5 Top-Ranked Stocks With Rising P/E for Solid Returns
by Sanghamitra Saha
Tap five stocks with increasing P/E ratios to try out a different approach. These stocks include Nektar Therapeutics (NKTR), Energous (WATT), DocuSign (DOCU), OptiNose (OPTN) and Canadian Solar (CSIQ).
Nektar (NKTR) Stock Surges 75% in a Week: Here's Why
by Zacks Equity Research
Nektar's (NKTR) shares rally almost 75% in a week on corrected efficacy data for rezpeg studies, earlier miscalculated by Eli Lilly.
Nektar Therapeutics (NKTR) Q2 Loss Narrows, Sales Miss
by Zacks Equity Research
Nektar (NKTR) incurs a narrower-than-expected second-quarter loss but misses on revenues.
Nektar Therapeutics (NKTR) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Nektar (NKTR) delivered earnings and revenue surprises of 10% and 2.13%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Zoetis (ZTS) Moves 6.9% Higher: Will This Strength Last?
by Zacks Equity Research
Zoetis (ZTS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Why Is Nektar (NKTR) Down 19.7% Since Last Earnings Report?
by Zacks Equity Research
Nektar (NKTR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.